diabetes
Sanofi celebrates EU approvals
February 5, 2013Sales and Marketing Lyxumia, Sanofi, Zaltrap, diabetes
Sanofi is celebrating after diabetes treatment Lyxumia (lixisenatide) and metastatic colorectal cancer (mCRC) drug Zaltrap received authorisation in Europe. The …
NICE rejects Forxiga
February 1, 2013Sales and Marketing AstraZeneca, BMS, Forxiga, NICE, diabetes
NICE has given the thumbs-down to AstraZeneca and Bristol-Myers Squibb’s first-in-class type II diabetes treatment Forxiga. The drug was approved …
Takeda gets US diabetes approval
January 28, 2013Sales and Marketing FDA, Nesina, Takeda, diabetes
Takeda has been given US approval for its diabetes drug Nesina and two variations on it for the treatment of …
Janssen’s diabetes drug Invokana recommended
January 11, 2013Sales and Marketing Janssen, SGLT2, canagliflozin, diabetes, invokana
An FDA advisory committee has recommended Janssen’s new diabetes treatment canagliflozin for approval. To be marketed under the name Invokana, …
Boehringer hands back Lilly drug
January 8, 2013Research and Development, Sales and Marketing Boehringer, Tradjenta, diabetes, lilly
Boehringer Ingelheim has handed back one of Eli Lilly’s investigational diabetes drugs as a result of ‘independent strategic portfolio considerations’. …
Sanofi – aiming for number one in the world’s biggest diabetes market
December 18, 2012Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing China, Sanofi, diabetes, obesity
Sanofi is no different from any other major pharma company in seeing China as the single most important growth market …
Trajenta may reduce stroke damage
December 4, 2012Research and Development, Sales and Marketing Boehringer, EMA, Trajenta, diabetes, linagliptin
Boehringer Ingelheim’s diabetes drug Trajenta could one day be used to minimise the effects of brain damage following stroke. Scientists …
Forxiga approved in European Union
November 15, 2012Sales and Marketing AstraZeneca, BMS, Forxiga, diabetes
AstraZeneca and Bristol-Myers Squibb’s first-in-class type II diabetes treatment Forxiga has been approved in Europe – a major filip for …
Diabetes softens generics blow for Sanofi
October 30, 2012Sales and Marketing Eloxatin, Plavix, Sanofi, diabetes, emerging markets, patent cliff
Sanofi has unveiled its results for the third quarter, with news that the damage done by patent expiries has not …
Trajenta added to insulin recommended in Europe
September 26, 2012Sales and Marketing Boehringer Ingelheim, Trajenta, diabetes
The CHMP has recommended that Boehringer Ingelheim and Eli Liily and Co’s diabetes brand Trajenta should be approved as add-on …
Online programme to help diabetes patients
September 14, 2012Medical Communications, Sales and Marketing Boehringer, diabetes, lilly
Boehringer Ingelheim and Eli Lilly have launched an online initiative which they say will help diabetes sufferers make simple lifestyle …
Boehringer signs diabetes research deal
September 7, 2012Sales and Marketing Boehringer, diabetes, obesity
Boehringer Ingelheim has signed a four-year research agreement with a top Swiss university to look at the underlying causes of …
Charity launches ‘Diabetes App Challenge’
August 21, 2012Medical Communications apps, diabetes, digital
Diabetes UK has launched its Diabetes App Challenge for younger insulin dependent patients. The Diabetes App Challenge wants people with …
Generic Actos gains FDA approval
August 20, 2012Sales and Marketing Actos, Mylan, Ranbaxy, Takeda, diabetes, generic
Takeda’s big-selling diabetes pill Actos will have its US sales decimated after the FDA approves three copycat versions of the …
Diabetes prescriptions jump by 50% in England
August 15, 2012Sales and Marketing Humalog, Januvia, NHS, diabetes, spending
Diabetes prescriptions in England have for the first time topped 40 million this year, a rise of nearly 50% compared …
Latest content
